Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Ltd has received encouraging feedback from the FDA for its ALA-101 treatment for blood cancers, paving the way for a phase 1 clinical trial. The FDA’s pre-IND response supports Arovella’s development plans, providing a clear direction for an IND submission slated for early 2025. This milestone is significant as ALA-101 is an advanced allogeneic CAR-iNKT cell therapy, and its development could benefit Arovella’s other cancer treatment programs.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
